IL-1β centrality via canakinumab trial
de Koning HD, et al.
Arthritis Res Ther · 2015
Grade Bcohortn=8
Key Findings
- ●IL-1β centrality demonstrated
- ●PBMCs hyperresponsive to LPS
Referenced in (1 disease)
ID: pmid-26198339DOI: 10.1186/s13075-015-0709-6PMID: 26198339